https://www.selleckchem.com/pr....oducts/plerixafor-8h
PURPOSE OF REVIEW Treatment of Peyronie's disease with collagenase Clostridium histolyticum (CCh) has gained world-wide adoption following the phase III clinical trials IMPRESS I and II. However, the optimal treatment parameters remain largely unknown. Many groups have made modifications to CCh treatment in Peyronie's disease in recent years. This review aims to discuss the variations in CCh treatment reported and associated outcomes. RECENT FINDINGS Variations in CCh treatment protocols include administering higher CCh
Like
Comment
Share
